ObjectiveTo systematically evaluate the effectiveness and safety of cardiac contractility modulation (CCM) for the treatment of chronic systolic heart failure. MethodsThe databases of PubMed, ClinicalTrial.gov, Embase, Wanfang Data Knowledge Service Platform, and China National Knowledge Infrastructure were retrieved by computer, and the case-control trials related to CCM for treating chronic systolic heart failure were screened. After data extraction and literature quality evaluation, Meta analysis was performed by using RevMan 5.4 software. ResultsA total of 6 literature was enrolled, including 1089 patients, therein, there were 544 cases in the CCM group, and 545 cases in the control group. The results of Meta-analysis revealed that compared with the control group, the CCM group exhibited reduced readmission because of aggravation of heart failure, an increased score of Minnesota Living with Heart Failure Questionnaire, and a prolonged distance of 6-minute walk test (P＜0.05), but no statistically significant difference in the all-cause mortality, all-cause readmission rate, and incidence rate of arrhythmia was found between the two groups (P＞0.05). ConclusionCompared with single drug therapy, CCM combined with drug therapy can effectively improve exercise tolerance of patients with chronic systolic heart failure, ameliorate their cardiac function and quality of life, reduce risk of readmission because of heart failure aggravation, which is expected to be regarded as novel approach to this disease.

无